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Abstract
Background: It is frequently important to identify the prognosis of fulminant hepatic failure (FHF)
patients as this will influence patient management and candidacy for liver transplantation.
Therefore, a novel scoring system based on metabonomics combining with multivariate logistic
regression was developed to predict the prognosis of FHF mouse model.
Methods: BALB/c mice were used to construct FHF model. Parts of plasma were collected at 4,
5, and 6-h time points after treatment, respectively, and detected using gas chromatography/time-
of-flight mass spectrometry (GC/TOFMS). The acquired data were processed using partial least
square discriminant analysis (PLS-DA). The metabolic markers identified were used to construct a
scoring system by multivariate regression analysis.
Results: 28 mice of survival group and 28 of dead group were randomly selected and analyzed. PLS
regression analysis showed that both the PLS models of 5 h and 6 h after d-galactosamine/
lipopolysaccharide treatment demonstrated good performances. Loadings plot suggested that
phosphate, beta-hydroxybutyrate (HB), urea, glucose and lactate concentrations in plasma had the
highest weightings on the clustering differences at the three time points. By the multivariate logistic
regression analysis, the death/survival index (DSI) was constructed based on relative
concentrations of HB, urea and phosphate. It provided general accurate rate of prediction of 93.3%
in the independent samples.
Conclusions: The novel scoring system based on metabonomics combining with multivariate
logistic regression is accurate in predicting the prognosis of FHF mouse model and may be referred
in clinical practice as a more useful prognostic tool with other available information.
Background
Fulminant hepatic failure (FHF) is a syndrome character-
ized by an abrupt onset, hepatic encephalopathy and
coagulation abnormality in the absence of preexistent
liver disease [1]. The syndrome carries high morbidity and
mortality. Orthotopic liver transplantation (OLT) has
been increasingly the most important way for FHF, which
decreased fatality rate with FHF from 85% to 35% [2].
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Unfortunately, the application of OLT has remained low
for its higher expense and less donor organs, and a high
percentage of patients die before an organ is available [3].
Alternatively, with the earlier use of artificial liver support-
ing system (ALSS), the nonsurgical medicinal therapy was
increasingly improved. Early diagnosis and prognosis
identification of FHF patients is likely to result in an inter-
vention at an earlier stage of the disease and, thus, an
increased likelihood of treatment success.
In previous studies, individual compounds including lac-
tate, phosphorus among others were proposed to predict
patient outcome in FHF [4,5]. However, their prognostic
value is debatable [6]. Application of multivariate models
has been improved prediction accuracy of FHF outcome.
The Clichy criteria developed in patients with hepatitis B
consisted of factor V level, patient age, HBsAg and serum
alfa-fetoprotein level. The King's College Hospital (KCH)
criteria, which was performed based on a retrospective
analysis of 585 FHF patients, have been the most widely
applied [7]. However, a retrospective study about both cri-
teria in FHF patients reported lower predictive values with
the positive predictive values (PPV) at 73% to 79% and
the negative predictive values (NPV) at < 50%[4]. The
Model for End-Stage Liver Disease (MELD) scoring system
is a reliable measure of short-term mortality risk in
patients with end-stage chronic liver disease. However, as
a predictor of death from FHF, MELD score did not pro-
vide more information than the King's College Hospital
criteria or international normalized ratio (INR) alone [8].
Therefore, better prognostic model to identify FHF
patients who are likely to survive is needed.
After proposed by Nicholson in 1999, metabonomics has
increasingly attained attention in recent years, applied to
study various human diseases such as coronary artery dis-
ease and cancers, and provided new insights into the reg-
ulatory investigations [9-11]. One of the most important
objectives of metabonomic studies is to identify novel
metabolic biomarkers from biofluids in various physio-
logical and pathological conditions. In the previous stud-
ies, we reported the dynamics of metabolic profiles in d-
galactosamine/lipopolysaccharide (GalN/LPS)-treated
BALB/c mouse model, and identified 5 biomarkers
including phosphate, β-hydroxybutyrate (HB), urea, glu-
cose and lactate which may constitute a set of markers for
the early diagnosis and prognosis of FHF [12,13]. But how
to predict the prognosis based on plasma levels of these
metabolic biomarkers? In this study, using metabonomic
methods based on gas chromatography/time-of-flight
mass spectrometry (GC/TOFMS) combined with multi-
variate logistic regression analysis, we aimed to derive a
regression model consisted of several metabolic biomark-
ers for monitoring FHF, and make a basis of related inves-
tigations in clinical practice.
Methods
Materials
Male BALB/c mice (18-22 g) were purchased from the
Academy of Military Medical Sciences (Beijing, China),
housed in a standard animal laboratory with constant
conditions of temperature, humidity, and 12 h light-dark
cycles, and allowed free access to standard laboratory
chow and water. Animal studies were carried out in
accordance with the Chinese National Research Council
guidelines and approved by the Subcommittee on
Research Animal Care and Laboratory Animal Resources
of the Peking University People's Hospital. Absolute etha-
nol and chloroform were obtained from Sigma (Sigma-
Aldrich Chemical Co. Steinheim, Germany) and used in
the extraction of polar metabolites. N-methyl-N-trimeth-
ylsilyltrifluoroacetamide (MSTFA), methoxyamine hydro-
chloride and pyridine were obtained from Sigma and used
to derivatize pure metabolites. Ribitol was used as an
internal reference. Doubly distilled water was used in the
preparation of standard and sample solutions.
Construction of experimental FHF model
The FHF model was established as described previously
[13]. The model group was intraperitoneally treated with
0.6 g/kg GalN followed by 8 μg/kg LPS, and GalN/LPS
treated mice were classed into a survival group and a dead
group. Five mice of each group were randomly selected for
collection of retro-orbital blood at 4, 5 and 6 h after treat-
ment. Additional samples obtained at 5 h after treatment
from 23 mice of the survival group and 23 mice of the
dead group were also analyzed. Blood was collected into
tubes containing 10 μL solution of 4% EDTA, immedi-
ately placed on ice and centrifuged at 3000 rpm for 10
min at 4°C. Plasma samples were stored at -80°C until
metabonomic analysis.
Assessment of liver injury
Plasma levels of alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST) and T-bilirubin (TBIL), meas-
ured with a 7170A automatic analyzer (Hitachi, Japan),
were used to assess the extent of liver injury.
Plasma samples preprocessing and GC/TOFMS analysis
In this study, processing of plasma samples followed a
protocol described in ref. [13]. Briefly, the thawed plasma
samples were quenched by pure methanol and extracted
by chloroform. The upper phase was separated and then
evaporated to dryness under a stream of N2 gas. At last,
the precipitation was derivatized by methoximation and
trimethylsilylation.
The GC/TOFMS system consists of an HP 6890 gas chro-
matograph and a time-of-flight mass spectrometer
(Waters Co., Milford, Massachusetts, USA). As described
in previous study [13], the pretreated plasma samplesBMC Gastroenterology 2009, 9:99 http://www.biomedcentral.com/1471-230X/9/99
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were analyzed. Identity of GC/MS detected peaks was
established by comparing their mass spectra and retention
index with those available in the NIST02 library and those
of commercially available reference compounds. As for
some overlapping peaks, one solution to identify all the
peaks in the chromatogram is to use a deconvolution soft-
ware like AMDIS prior to library searching [14].
Data processing
After exported from MarkerLynx, All the collected data
from the plasma samples were processed with SIMCA-P
plus (version10.0, Umetrics AB, Sweden) as described pre-
viously [12,13], in which a range of multivariate statistical
analysis were conducted. A data matrix was constructed
with the sample IDs as observations and the peaks/reten-
tion times as the response variables. It was represented in
a K-dimensional space (where K stands for the number of
variables), and then projected and reduced to a few prin-
cipal components that can maximize the separation
between classes [15]. Here, partial least square discrimi-
nant analysis (PLS-DA) was used to process the required
GC/TOFMS data. For PLS analysis, data were visualized by
plotting principal component (PC) scores. In the scores,
each point represents an individual sample. The plots
allow the recognition of clusters of samples with similar
scores. Each score plot has a loading plot associated with
it, which allows in identifying the spectral regions (metab-
olites) responsible for the sample clustering observed [3].
To construct a regression model, multivariate regression
analysis was performed based on 56 plasma samples at 5
h after GalN/LPS treatment using the Statistical Package
for Social Scientists. The analysis was carried out with the
binary response being dead or survived. This model was
performed with a model group of 13 randomly selected
survival samples and 13 dead samples. A validation group
consisted of the remained 30 samples. The linear combi-
nation of those biomarkers identified in the metabo-
nomic analysis was then applied to the logistic regression
formula to predict the probability of FHF prognosis based
on a formula score.
Results
Assessment of liver injury at 5 h and 6 h after treatment
Compared with plasma levels of ALT, AST, and TBIL in the
survival group, they were significantly increased in the
dead group at 6 h after GalN/LPS treatment. However,
plasma ALT, AST, and TBIL levels showed no significant
differences between the two groups at 5 h time point
(Table 1).
Absence of ribital in plasma samples of BALB/c mice
To confirm absence of ribitol in plasma of BALA/c mice,
two samples from the same mouse were analyzed. Ribitol
was added to one of them during plasma pretreatment.
Figure 1 showed the peak of ribitol in the total ion current
(TIC) of the sample with ribitol (upper), and there was no
corresponding peak in the same retention time of TIC of
another sample without ribitol (lower). Therefore, ribitol
can be used as an internal standard to correct for minor
variations during sample preparation and analysis.
Partial least square-discriminant analysis
PLS is a supervised statistical method and additional
knowledge (Y-variables) must be included to "supervise"
the independent data (X-variables). In this study, discri-
minant analysis was performed using PLS. The PLS diag-
nostic is tabulated in Table 2 after modeling. Here R2X
and R2Y are the fractions of X-variation and Y-variation
modeled for specific component, respectively. Q2Y is the
estimate of how well the model predicts the Y-variables
through a default 7-fold cross-validation. The cumulative
values of R2Y and Q2Y of the selected components close
to one indicate a perfect fitting. So the diagnostic results
indicated both the PLS models of 5 h and 6 h after GalN/
LPS treatment demonstrated good performances based on
the acquired metabonomics data.
Identification of metabolic markers for distinguishing 
between the survival and dead groups
In previous studies, clustering analysis of data collected at
4 h, 5 h and 6 h was performed using PLS-DA. Score plots
showed distinct clustering differences between the sur-
vival and dead groups at 5 h and 6 h after GalN/LPS treat-
ment. Loading plots reveal the impact of metabolites on
the clustering results: the closer to zero, the smaller the
influence of a linear metabolite combination. All of the
three loading plots in Figure 2 suggested that phosphate,
HB, urea, glucose and lactate concentrations in plasma
had the highest weightings on the clustering differences
although there was no clear cluster at 4 h.
Table 1: Assessment of liver injury at 5 h and 6 h after GalN/LPS treatment
Parameters Survival group Dead group P
5 h ALT (U/L) 698.52 ± 256.37 722.34 ± 242.87 4.13E-01
AST (U/L) 712.45 ± 301.23 745.21 ± 297.38 5.42E-02
TBIL (μmol/L) 3.12 ± 0.96 3.23 ± 1.13 1.75E-01
6 h ALT (U/L) 762.12 ± 212.51 1967.34 ± 1032.78 2.15E-03
AST (U/L) 801.92 ± 246.73 1874.54 ± 952.65 4.02E-04
TBIL (μmol/L) 3.37 ± 1.02 5.12 ± 1.31 3.23E-03BMC Gastroenterology 2009, 9:99 http://www.biomedcentral.com/1471-230X/9/99
Page 4 of 7
(page number not for citation purposes)
Regression analysis of data at 5 h point
Backward stepwise, which is one of three main
approaches to automating the selection of explanatory
variables for inclusion in a regression model, was used in
the multivariate logistic regression analysis. In backward
selection, all variables are included in the initial model,
and then removed sequentially until a final model is pro-
duced. After 3 steps, lactate and glucose were removed,
and other variables (HB, urea and phosphate) were used
to calculate a nomogram. The derived nomogram, the
death/survival index (DSI) was:
Probability of survival as compared to death was cali-
brated from the logistic regression analysis using the
equation as follows:
The resulting value was defined as the DSI, with DSI < 0
incrementally favored a prognosis of "death", while DSI >
0 corresponded to a higher likelihood of a prognosis of
"survival".
Validation of the death/survival index (DSI)
We further validated and calibrated the DSI by comparing
the predicted probability of FHF prognosis based on DSI
with the validation group. Based on the cut-off value of
DSI as above, one of 15 survival samples and one of 15
dead samples were removed, and general accurate rate of
prediction was 93.3%. Figure 3 shows predicted probabil-
ity of survival based on DSI. DSI of >0.65 or < - 0.65 pro-
vided a relatively clear diagnosis, corresponding to a
93.3% or 6.7% probability of survival.
Discussion
It is well known that various biological factors affect the
metabolic composition of biological fluids [15]. They are
intrinsic (e.g. age, gender) and extrinsic (e.g. diet, smok-
0 027 0 031 0 035 5 732 .. . . . HB UREA PHOS +−−
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Absence of ribital in plasma samples of BALB/c mice Figure 1
Absence of ribital in plasma samples of BALB/c mice. 
The peak of ribitol was showed in TIC of the sample with 
ribitol (upper), and there was no corresponding peak in the 
same retention time of TIC of another sample without ribitol 
(lower).
Table 2: Modeling diagnostic of the metabolic data derived from 
plasma samples of various time points after GalN/LPS 
treatment
PLS model Components Modeling diagnostic
R2X R2Y Q2Y
4 h 1 0.186 0.288 0.225
2 0.256 0.412 0.368
3 0.335 0.556 0.406
5 h 1 0.351 0.742 0.701
2 0.471 0.876 0.812
3 0.504 0.915 0.857
6 h 1 0.367 0.781 0.666
2 0.433 0.896 0.817
3 0.493 0.941 0.862
Note. 1, 2, or 3 indicates quantities of components contributed to 
cumulative values. R2X is the fraction of X-variation; R2Y is the 
fraction of Y-variation; Q2Y is the cumulated cross-validation for 
R2Y. R2X, R2Y and Q2Y are all ranged from 0 to 1.
Identification of metabolic markers for distinguishing  between survival and dead groups Figure 2
Identification of metabolic markers for distinguishing 
between survival and dead groups. Phosphate, HB, urea, 
glucose and lactate concentrations in plasma had the highest 
weightings on the clustering differences at 4 h, 5 h and 6 h 
after GalN/LPS treatment, although there was no clear clus-
ter at 4 h.BMC Gastroenterology 2009, 9:99 http://www.biomedcentral.com/1471-230X/9/99
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ing, drugs). External variation can be minimized in stud-
ies with laboratory animals, whereas in humans these
factors are more difficult to control. Alternatively, because
of higher fees, more explicit method and larger data, it is
difficult to directly apply GC/TOFMS for clinical practice
now. However, it is easy and applicable to construct a
scoring system for early identification of diseases' progno-
sis based on metabolic biomarkers.
The rapidly developing field of metabonomics offered a
new method to identify biomarkers. Nuclear magnetic
resonance (NMR) and mass spectrometry (MS) are the
most frequently employed methods of detection in the
analysis of the metabolome [16,17]. NMR provides a
rapid, non-destructive, high-throughput method that
requires little or no sample preparation, and however, its
equipment cost is much higher and its sensitivity is lower
limited than MS. The most advantages of MS are its high
sensitivity, and high-throughput. Furthermore, the com-
bination of separation techniques with MS tremendously
expands the capability of the chemical analysis of highly
complex biological samples. Among the tandem tech-
niques investigated, the coupling of capillary gas chroma-
tography to MS (GC/MS) proved to be a potentially useful
method based on its high sensitivity, peak resolution and
reproducibility. The availability of GC/MS electron
impact (EI) spectral libraries further facilitates the identi-
fication of diagnostic biomarkers and aids the subsequent
mechanistic elucidation of the biological or pathological
variations [14].
In the clinical arena, it is frequently important to identify
the prognosis of FHF patients (survival or death) as this
will influence patient management and candidacy for
liver transplantation. Despite a number of novel and
sometimes expensive biomarkers that have been devel-
oped and evaluated, most of these have not been repro-
ducibly demonstrated to perform more effectively than
those traditional and inexpensive laboratory values [4,8].
GC/TOFMS of biofluids and tissues coupled with appro-
priate statistical methods offer a novel and robust
approach for identifying individual metabolites or combi-
nations of metabolites that may serve as pathological
biomarkers. This results in the generation of an endog-
enous metabolic profile that has the potential to reveal
characteristics indicative of disease status.
To construct a model for early prediction of FHF progno-
sis, in previous studies we investigated the dynamics of
metabolic intermediates and metabolic profiles using a
GalN/LPS-treated BALB/c mouse model of FHF prior to
clinical FHF patients [12,13]. In this study, PLS-DA was
used to obtain a list of potential biomarkers which are sta-
tistically significant and which separate one class from
another. The PLS diagnostic tabulated in Table 2 con-
tained three factors, showing the performance statistics of
R2X, R2Y and Q2Y. R2X is the cumulative modeled varia-
tion in the GC/TOFMS response variables, X; R2Y is the
cumulative modeled variation in the observation varia-
bles, Y; and Q2Y is the cumulative predicted variation in
Y, according to cross-validation. The ranges of these
parameters are 0-100%, where 100% indicates a perfect fit
[18]. So the diagnostic results indicated both the PLS
models of 5 h and 6 h after GalN/LPS treatment demon-
strated good performances based on the acquired metab-
onomics data. That means distinct clustering (survival and
death) was obtained at 5 h and 6 h time points. To con-
struct an early prediction model, we selected 5 h time
point when there was no significant difference in plasma
levels of ALT, AST, and TBIL between the two groups.
Loadings plot represented the impact of metabolites on
the clustering results: the closer to zero, the smaller the
influence of a linear metabolite combination. Phosphate,
HB, urea, glucose and lactate concentrations in plasma
had the highest weightings on the clustering differences at
the three time points, although there was no clear cluster
at 4 h after treatment. It was suggested that a combination
of phosphate, HB, urea, glucose and lactate concentra-
tions in the plasma could potentially be used to separate
the survival and dead groups earlier.
Based on the set of potential metabolic biomarkers
including phosphate, HB, urea, glucose and lactate identi-
fied using GC/TOFMS combined with multivariate statis-
tics, we attempted to form a scoring system to early
identify FHF outcomes. By the multivariate logistic regres-
sion analysis, lactate and glucose were removed, and then
the death/survival index (DSI) was constructed based on
relative concentrations of other variables (HB, urea and
phosphate) and validated well in the samples from inde-
pendent validation group. The DSI maintains important
Predicted probability of survival based on the death/survival  index (DSI) Figure 3
Predicted probability of survival based on the death/
survival index (DSI). DSI of >0.65 or < - 0.65 provided a 
relatively clear diagnosis, corresponding to a 93.3% or 6.7% 
probability of survival. Squares represent dead mice, and dia-
monds represent surviving mice.BMC Gastroenterology 2009, 9:99 http://www.biomedcentral.com/1471-230X/9/99
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and unique methodological aspects that enhance its util-
ity as compared to other studies designed to predict FHF
prognosis. The use of logistic regression facilitated appro-
priate weighting of the parameters that comprise the DSI.
Alternatively, the DSI is a continuous variable, we can
identify the probability of FHF prognosis (survival or
death) based on the magnitude and dynamic change of
the DSI.
Conclusions
We have developed a novel scoring system that is highly
accurate in predicting the prognosis of FHF mouse model.
The methodological aspects based on metabonomic tech-
nologies combining with multivariate logistic regression
were constructed and may be referred in clinical practice.
As a useful prognostic tool, it may be complemented with
other available information such as traditional laboratory
values and clinical parameters.
Potential limitations
Various biological factors affect the metabolic composi-
tion of biological fluids, and these factors might be
involved in humans to different extend. Although our pre-
vious pilot result showed that changes of plasma phos-
phate, HB, urea, glucose and lactate levels in FHF patients
were consistent with those of FHF mouse model, it is
unknown whether the scoring system based on the five
metabolites would be applicable to predicting the prog-
nosis FHF seen in clinical practice. In addition, etiology of
FHF patients is complex, which can influence metabo-
nomics of body fluids. All of these need a further investi-
gation.
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